查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
眼科临床试验市场规模、份额和趋势分析报告：按产品、按阶段、按适应症、按赞助商类型、按地区、细分市场预测，2023-2030 年
市场调查报告书
商品编码
1301236

眼科临床试验市场规模、份额和趋势分析报告：按产品、按阶段、按适应症、按赞助商类型、按地区、细分市场预测，2023-2030 年

Ophthalmic Clinical Trials Market Size, Share & Trends Analysis Report By Product (Devices, Drugs), By Phase (Discovery Phase, Preclinical Phase, Clinical Phase), By Indication, By Sponsor Type, By Region, And Segment Forecasts, 2023 - 2030
出版日期: | 出版商: Grand View Research | 英文 150 Pages | 商品交期: 2-10个工作天内

价格

眼科临床试验市场增长和趋势

GrandView Research, Inc.最新报告显示，到2030年，全球眼科临床试验市场规模预计将达到25亿美元，预测期内復合年增长率为6.6%。

技术的发展和对更有效的眼部疾病治疗方法日益增长的需求正在推动眼科临床试验市场的快速扩张。製药公司、医疗器械製造商和合同研究组织 (CRO) 是该领域的主要贡献者。

青光眼、黄斑变性和糖尿病视网膜病变等眼部疾病患病率的上升正在推动该行业的发展。随着全球人口老龄化和眼病变得更加普遍，眼科临床试验市场预计将进一步增长。此外，基因研究和个性化医疗的发展可能会刺激该领域的创新，从而为眼部疾病提供更专业、更有效的治疗方法。

随着眼科研究人员专注于开发和营销新型眼科药物，对临床试验的需求预计将会增加。此外，为满足新兴经济体对罕见眼病未满足的需求而采取的举措预计将支持眼科临床试验市场的增长。例如，根据世界卫生组织（WHO）2021年10月发布的《视障者残疾报告》，估计约有22亿人患有分离视力或近视，其中至少有一半的病例是可以预防的在适当治疗的帮助下。

COVID-19 大流行对眼科临床试验市场产生了重大影响。在临床试验方面，疫情推迟了新试验的开始和患者入组。此外，多个临床试验中心被迫关闭，显着减少了患者就诊和数据收集。疫情加速了远程和虚拟临床试验技术的部署，使正在进行的临床试验得以继续，并开始新的临床试验。通过采用这些技术，缓解了大流行带来的一些困难，例如旅行限制和社会隔离的需要。

眼科临床试验市场亮点

  • 2022年，医药板块占比最大，达75.5%。由于对各种眼部疾病的创新和有效药物疗法的需求不断增长，该细分市场占据了市场主导地位。
  • 在分析期间，青光眼细分市场预计将以 7.3% 的复合年增长率增长。主要公司之间加强合作和伙伴关係开发新型青光眼治疗方法正在推动该领域的发展。
  • 2022 年，临床阶段细分市场以 79.4% 的销售份额占据市场主导地位。政府和私营公司为进行临床试验而增加的研发投资正在推动该行业的增长。
  • 2022年，该市场将由製药/生物製药公司主导，收入份额为41.8%。眼科临床试验的主要赞助商是製药和生物製药公司，他们拥有开发和商业化新疗法的资源和知识。
  • 预计在分析期间，亚太地区的复合年增长率将达到 7.2%。这主要是由于想要参与临床试验的患者群体较多。此外，印度等新兴市场临床试验的成本效益进一步吸引西方国家开展临床研究，推动该地区眼科临床试验市场的增长。

目录

第一章 调查方法和范围

  • 市场细分和范围
  • 区域范围
  • 估计/预测时间表
  • 目的
  • 调查方法
  • 信息采购
  • 信息或数据分析
  • 市场形成和验证
  • 型号详情
  • 二级信息列表
  • 缩略语表

第二章执行摘要

  • 市场展望
  • 分部展望
  • 竞争考虑

3.眼科临床试验市场变量、趋势和范围

  • 市场谱系展望
    • 母公司市场展望
    • 相关/辅助市场展望
  • 市场动态
    • 市场驱动力分析
    • 市场约束因素分析
  • 眼科临床试验市场分析工具
    • 行业分析-波特分析
    • PESTEL 分析
    • COVID-19 感染的影响分析

第四章眼科临床试验市场：产品评估和趋势分析

  • 眼科临床试验市场，副产品：细分仪表板
  • 眼科临床试验市场，副产品：变异分析
    • 设备
    • 药物

第五章眼科临床试验市场：适应症估计和趋势分析

  • 眼科临床试验市场，按适应症：细分仪表板
  • 眼科临床试验市场，按适应症：变异分析
    • 黄斑变性
    • 青光眼
    • 干眼症
    • 视网膜病变
    • 葡萄膜炎
    • 黄斑水肿
    • 睑缘炎
    • 白内障
    • 视神经病变
    • 其他

第六章眼科临床试验市场：阶段估计和趋势分析

  • 眼科临床试验市场，按阶段：细分仪表板
  • 眼科临床试验市场，按阶段：变异分析
    • 发现阶段
    • 临床前阶段
    • 临床分期

第七章眼科临床试验市场：申办者类型估计和趋势分析

  • 眼保健临床试验市场，按赞助商类型：细分仪表板
  • 眼科临床试验市场，按赞助商类型：变异分析
    • 製药/生物製药公司
    • 医疗器械公司
    • 其他

第八章眼科临床试验市场：区域估计和趋势分析

  • 2022 年和 2030 年区域市场份额分析
  • 区域市场仪表板
  • 全球区域市场快照
  • 北美
    • 2018-2030 年市场估计和预测（收入）
    • 美国
    • 加拿大
  • 欧洲
    • 英国
    • 德国
    • 法国
    • 意大利
    • 西班牙
    • 丹麦
    • 瑞典
    • 挪威
  • 亚太地区
    • 日本
    • 印度
    • 中国
    • 韩国
    • 澳大利亚
    • 泰国
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 阿根廷
  • 多边环境协定
    • 南非
    • 沙特阿拉伯
    • 阿拉伯联合酋长国
    • 科威特

第9章 竞争格局

  • 市场进入者分类
    • 创新者
    • 市场领导者
    • 新兴玩家
    • 2022 年公司市场份额分析
  • 公司简介
    • Charles River Laboratories International, Inc
    • Laboratory Corporation of America Holdings
    • IQVIA
    • ICON Plc
    • Vial
    • Medpace
    • ProTrials Research, Inc.
    • Syneos Health
    • Worldwide Clinical Trials, Inc
    • ProRelix Services LLP.
Product Code: GVR-4-68040-085-8

Ophthalmic Clinical Trials Market Growth & Trends

The global ophthalmic clinical trials market size is expected to reach USD 2.5 billion by 2030 at a CAGR of 6.6% over the forecast period, according to a new report by Grand View Research, Inc. Technological developments and a rising need for more efficient eye disease treatments are driving the market for ophthalmology clinical trials to expand quickly. Pharmaceutical firms, medical equipment producers, and Contract Research Organizations (CROs) are a few of the major contributors to this sector.

The rising incidence of eye conditions, including glaucoma, macular degeneration, and diabetic retinopathy, is driving the industry. As the global population ages and eye illnesses become more common, the market for ophthalmology clinical trials is further anticipated to grow in the coming years. Additionally, developments in genetic research and personalized medicine are likely to spur innovation in this area, creating more specialized and efficient treatments for eye illnesses.

The demand for clinical trials will rise due to the increasing focus of ophthalmic researchers to develop and market novel ocular medicines. Furthermore, the initiatives adopted to fulfill the unmet needs in developing economies regarding rare ocular conditions are anticipated to support the growth of the ophthalmology clinical trials market. For instance, nearly 2.2 billion people are estimated to have separation or close-up vision impairment disorders, and of these, at least half, or 1 billion cases, can be avoided with the aid of appropriate treatment, according to the World Health Organization's October 2021 report on visually impaired people's impairment.

The COVID-19 pandemic has significantly impacted the ophthalmology clinical trials market. Clinical trials have been hampered by the epidemic, which has delayed the start of new trials and slowed patient enrollment. Additionally, several clinical study locations had to close, significantly reducing patient visits and data collecting. The epidemic has hastened the deployment of remote and virtual clinical trial technology, allowing for the continuation of ongoing trials and the start of new ones. Some of the difficulties brought on by the pandemic, including travel limitations and social seclusion requirements, have been mitigated partly by adopting these technologies.

Ophthalmic Clinical Trials Market Highlights

  • The drug segment accounted for the largest share of 75.5% in 2022. The segment dominated the market owing to the growing demand for innovative and efficient drug therapies for various eye ailments
  • The Glaucoma segment is expected to witness the highest CAGR of 7.3% during the analysis timeframe. The increase in collaboration and partnerships among the key players for developing novel glaucoma products spurs the segment's growth
  • The clinical phase segment dominated the market in 2022 with a revenue share of 79.4%. Increasing investments in R&D by the government, as well as private entities for the conduct of clinical studies, drives the segment's growth
  • The pharmaceutical/biopharmaceutical companies segment dominated the market in 2022 with a revenue share of 41.8%. The major sponsors of ophthalmology clinical trials are pharmaceutical and biopharmaceutical companies since they have the resources and knowledge to create and commercialize novel treatments
  • Asia Pacific is anticipated to register a lucrative CAGR of 7.2% during the analysis period. This is primarily due to a huge patient pool willing to undergo clinical trials. Furthermore, the cost-effective nature of clinical trials across developing economies such as India has further attracted Western countries to conduct clinical research, thereby boosting the region's growth in the ophthalmic clinical trials market

Table of contents

Chapter 1. Research Methodology And Scope

  • 1.1. Market Segmentation & Scope
    • 1.1.1. Segment Definitions
    • 1.1.2. Product
    • 1.1.3. Indication
    • 1.1.4. Phase
    • 1.1.5. Sponsor Type
  • 1.2. Regional Scope
  • 1.3. Estimates And Forecast Timeline
  • 1.4. Objectives
    • 1.4.1. Objective - 1
    • 1.4.2. Objective - 2
    • 1.4.3. Objective - 3
  • 1.5. Research Methodology
  • 1.6. Information Procurement
    • 1.6.1. Purchased Database
    • 1.6.2. GVR's Internal Database
    • 1.6.3. Secondary Sources
    • 1.6.4. Primary Research
  • 1.7. Information Or Data Analysis
    • 1.7.1. Data Analysis Models
  • 1.8. Market Formulation & Validation
  • 1.9. Model Details
    • 1.9.1. Commodity Flow Analysis
    • 1.9.2. Parent Market Analysis
  • 1.10. List Of Secondary Sources
  • 1.11. List Of Abbreviations

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Competitive Insights

Chapter 3. Ophthalmic Clinical Trials Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market Outlook
    • 3.1.2. Related/Ancillary Market Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
      • 3.2.1.1. Increasing Partnerships Between CROs And Drug Development Companies To Boost The Market Growth
      • 3.2.1.2. Growing Research Funding Pertaining To Ocular Therapeutics Is Another Prominent Factor Supporting The Growth Of The Ophthalmic Clinical Trials Market.
      • 3.2.1.3. Technological Innovations Pertaining to Ophthalmic Research to Boost The Market Growth
    • 3.2.2. Market Restraint Analysis
      • 3.2.2.1. Low Barriers to Market Penetration Have Resulted In Pricing Pressure
      • 3.2.2.2. Challenges Related to Quality Control
  • 3.3. Ophthalmic Clinical Trials Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Supplier Power
      • 3.3.1.2. Buyer Power
      • 3.3.1.3. Substitution Threat
      • 3.3.1.4. Threat Of New Entrant
      • 3.3.1.5. Competitive Rivalry
    • 3.3.2. PESTEL Analysis
    • 3.3.3. COVID-19 Impact Analysis

Chapter 4. Ophthalmic Clinical Trials Market: Product Estimates & Trend Analysis

  • 4.1. Ophthalmic Clinical Trials Market, By Product: Segment Dashboard
  • 4.2. Ophthalmic Clinical Trials Market, By Product: Movement Analysis
  • 4.3. Ophthalmic Clinical Trials Market Estimates & Forecasts, By Product, 2018 - 2030
    • 4.3.1. Devices
      • 4.3.1.1. Devices Ophthalmic Clinical Trials Market, 2018 to 2030 (USD Million)
      • 4.3.1.2. Surgical & Diagnostics Devices
      • 4.3.1.2.1. Surgical & Diagnostics Devices Ophthalmic Clinical Trials Market, 2018 to 2030 (USD Million)
      • 4.3.1.3. Vision Care Devices
      • 4.3.1.3.1. Vision Care Devices Ophthalmic Clinical Trials Market, 2018 to 2030 (USD Million)
    • 4.3.2. Drugs
      • 4.3.2.1. Drugs Ophthalmic Clinical Trials Market, 2018 to 2030 (USD Million)
      • 4.3.2.2. OTC Drugs
      • 4.3.2.2.1. OTC Drugs Ophthalmic Clinical Trials Market, 2018 to 2030 (USD Million)
      • 4.3.2.3. Prescription Drugs
      • 4.3.2.3.1. Prescription Drugs Ophthalmic Clinical Trials Market, 2018 to 2030 (USD Million)

Chapter 5. Ophthalmic Clinical Trials Market: Indication Estimates & Trend Analysis

  • 5.1. Ophthalmic Clinical Trials Market, By Indication: Segment Dashboard
  • 5.2. Ophthalmic Clinical Trials Market, By Indication: Movement Analysis
  • 5.3. Ophthalmic Clinical Trials Market Estimates & Forecasts, By Indication, 2018 - 2030
    • 5.3.1. Macular Degeneration
      • 5.3.1.1. Macular Degeneration Ophthalmic Clinical Trials Market, 2018 to 2030 (USD Million)
    • 5.3.2. Glaucoma
      • 5.3.2.1. Glaucoma Ophthalmic Clinical Trials Market, 2018 to 2030 (USD Million)
    • 5.3.3. Dry Eye Disease
      • 5.3.3.1. Dry Eye Disease Ophthalmic Clinical Trials Market, 2018 to 2030 (USD Million)
    • 5.3.4. Retinopathy
      • 5.3.4.1. Retinopathy Ophthalmic Clinical Trials Market, 2018 to 2030 (USD Million)
    • 5.3.5. Uveitis
      • 5.3.5.1. Uveitis Ophthalmic Clinical Trials Market, 2018 to 2030 (USD Million)
    • 5.3.6. Macular Edema
      • 5.3.6.1. Macular Edema Ophthalmic Clinical Trials Market, 2018 to 2030 (USD Million)
    • 5.3.7. Blepharitis
      • 5.3.7.1. Blepharitis Ophthalmic Clinical Trials Market, 2018 to 2030 (USD Million)
    • 5.3.8. Cataract
      • 5.3.8.1. Cataract Ophthalmic Clinical Trials Market, 2018 to 2030 (USD Million)
    • 5.3.9. Optic Neuropathy
      • 5.3.9.1. Optic Neuropathy Ophthalmic Clinical Trials Market, 2018 to 2030 (USD Million)
    • 5.3.10. Others
      • 5.3.10.1. Others Ophthalmic Clinical Trials Market, 2018 to 2030 (USD Million)

Chapter 6. Ophthalmic Clinical Trials Market: Phase Estimates & Trend Analysis

  • 6.1. Ophthalmic Clinical Trials Market, By Phase: Segment Dashboard
  • 6.2. Ophthalmic Clinical Trials Market, By Phase: Movement Analysis
  • 6.3. Ophthalmic Clinical Trials Market Estimates & Forecasts, By Phase, 2018 - 2030
    • 6.3.1. Discovery Phase
      • 6.3.1.1. Discovery Phase Ophthalmic Clinical Trials Market 2018 to 2030 (USD Million)
    • 6.3.2. Preclinical Phase
      • 6.3.2.1. Preclinical Phase Ophthalmic Clinical Trials Market 2018 to 2030 (USD Million)
    • 6.3.3. Clinical Phase
      • 6.3.3.1. Clinical Phase Ophthalmic Clinical Trials Market 2018 to 2030 (USD Million)

Chapter 7. Ophthalmic Clinical Trials Market: Sponsor Type Estimates & Trend Analysis

  • 7.1. Ophthalmic Clinical Trials Market, By Sponsor Type: Segment Dashboard
  • 7.2. Ophthalmic Clinical Trials Market, By Sponsor Type: Movement Analysis
  • 7.3. Ophthalmic Clinical Trials Market Estimates & Forecasts, By Phase, 2018 - 2030
    • 7.3.1. Pharmaceutical/biopharmaceutical Companies
      • 7.3.1.1. Pharmaceutical/biopharmaceutical Companies Ophthalmic Clinical Trials Market 2018 to 2030 (USD Million)
    • 7.3.2. Medical Device Companies
      • 7.3.2.1. Medical Device Companies Ophthalmic Clinical Trials Market 2018 to 2030 (USD Million)
    • 7.3.3. Others
      • 7.3.3.1. Others Ophthalmic Clinical Trials Market 2018 to 2030 (USD Million)

Chapter 8. Ophthalmic Clinical Trials Market: Regional Estimates & Trend Analysis

  • 8.1. Regional Market Share Analysis, 2022 & 2030
  • 8.2. Regional Market Dashboard
  • 8.3. Global Regional Market Snapshot
  • 8.4. North America
    • 8.4.1. Market Estimates and Forecast, 2018 - 2030 (Revenue, USD Million)
    • 8.4.2. U.S.
      • 8.4.2.1. Key Country Dynamics
      • 8.4.2.2. Competitive Scenario
      • 8.4.2.3. Regulatory Framework
      • 8.4.2.4. U.S. Market Estimates and Forecasts, 2018 - 2030
    • 8.4.3. Canada
      • 8.4.3.1. Key Country Dynamics
      • 8.4.3.2. Competitive Scenario
      • 8.4.3.3. Regulatory Framework
      • 8.4.3.4. Canada Market Estimates and Forecasts, 2018 - 2030
  • 8.5. Europe
    • 8.5.1. UK
      • 8.5.1.1. Key Country Dynamics
      • 8.5.1.2. Competitive Scenario
      • 8.5.1.3. Regulatory Framework
      • 8.5.1.4. UK Market Estimates and Forecasts, 2018 - 2030
    • 8.5.2. Germany
      • 8.5.2.1. Key Country Dynamics
      • 8.5.2.2. Competitive Scenario
      • 8.5.2.3. Regulatory Framework
      • 8.5.2.4. Germany Market Estimates and Forecasts, 2018 - 2030
    • 8.5.3. France
      • 8.5.3.1. Key Country Dynamics
      • 8.5.3.2. Competitive Scenario
      • 8.5.3.3. Regulatory Framework
      • 8.5.3.4. France Market Estimates and Forecasts, 2018 - 2030
    • 8.5.4. Italy
      • 8.5.4.1. Key Country Dynamics
      • 8.5.4.2. Competitive Scenario
      • 8.5.4.3. Regulatory Framework
      • 8.5.4.4. Italy Market Estimates and Forecasts, 2018 - 2030
    • 8.5.5. Spain
      • 8.5.5.1. Key Country Dynamics
      • 8.5.5.2. Competitive Scenario
      • 8.5.5.3. Regulatory Framework
      • 8.5.5.4. Spain Market Estimates and Forecasts, 2018 - 2030
    • 8.5.6. Denmark
      • 8.5.6.1. Key Country Dynamics
      • 8.5.6.2. Competitive Scenario
      • 8.5.6.3. Regulatory Framework
      • 8.5.6.4. Denmark Market Estimates and Forecasts, 2018 - 2030
    • 8.5.7. Sweden
      • 8.5.7.1. Key Country Dynamics
      • 8.5.7.2. Competitive Scenario
      • 8.5.7.3. Regulatory Framework
      • 8.5.7.4. Sweden Market Estimates and Forecasts, 2018 - 2030
    • 8.5.8. Norway
      • 8.5.8.1. Key Country Dynamics
      • 8.5.8.2. Competitive Scenario
      • 8.5.8.3. Regulatory Framework
      • 8.5.8.4. Norway Market Estimates and Forecasts, 2018 - 2030
  • 8.6. Asia Pacific
    • 8.6.1. Japan
      • 8.6.1.1. Key Country Dynamics
      • 8.6.1.2. Competitive Scenario
      • 8.6.1.3. Regulatory Framework
      • 8.6.1.4. Japan Market Estimates and Forecasts, 2018 - 2030
    • 8.6.2. India
      • 8.6.2.1. Key Country Dynamics
      • 8.6.2.2. Competitive Scenario
      • 8.6.2.3. Regulatory Framework
      • 8.6.2.4. India Market Estimates and Forecasts, 2018 - 2030
    • 8.6.3. China
      • 8.6.3.1. Key Country Dynamics
      • 8.6.3.2. Competitive Scenario
      • 8.6.3.3. Regulatory Framework
      • 8.6.3.4. China Market Estimates and Forecasts, 2018 - 2030
    • 8.6.4. South Korea
      • 8.6.4.1. Key Country Dynamics
      • 8.6.4.2. Competitive Scenario
      • 8.6.4.3. Regulatory Framework
      • 8.6.4.4. South Korea Market Estimates and Forecasts, 2018 - 2030
    • 8.6.5. Australia
      • 8.6.5.1. Key Country Dynamics
      • 8.6.5.2. Competitive Scenario
      • 8.6.5.3. Regulatory Framework
      • 8.6.5.4. Australia Market Estimates and Forecasts, 2018 - 2030
    • 8.6.6. Thailand
      • 8.6.6.1. Key Country Dynamics
      • 8.6.6.2. Competitive Scenario
      • 8.6.6.3. Regulatory Framework
      • 8.6.6.4. Thailand Market Estimates and Forecasts, 2018 - 2030
  • 8.7. Latin America
    • 8.7.1. Brazil
      • 8.7.1.1. Key Country Dynamics
      • 8.7.1.2. Competitive Scenario
      • 8.7.1.3. Regulatory Framework
      • 8.7.1.4. Brazil Market Estimates and Forecasts, 2018 - 2030
    • 8.7.2. Mexico
      • 8.7.2.1. Key Country Dynamics
      • 8.7.2.2. Competitive Scenario
      • 8.7.2.3. Regulatory Framework
      • 8.7.2.4. Mexico Market Estimates and Forecasts, 2018 - 2030
    • 8.7.3. Argentina
      • 8.7.3.1. Key Country Dynamics
      • 8.7.3.2. Competitive Scenario
      • 8.7.3.3. Regulatory Framework
      • 8.7.3.4. Argentina Market Estimates and Forecasts, 2018 - 2030
  • 8.8. MEA
    • 8.8.1. South Africa
      • 8.8.1.1. Key Country Dynamics
      • 8.8.1.2. Competitive Scenario
      • 8.8.1.3. Regulatory Framework
      • 8.8.1.4. South Africa Market Estimates and Forecasts, 2018 - 2030
    • 8.8.2. Saudi Arabia
      • 8.8.2.1. Key Country Dynamics
      • 8.8.2.2. Competitive Scenario
      • 8.8.2.3. Regulatory Framework
      • 8.8.2.4. Saudi Arabia Market Estimates and Forecasts, 2018 - 2030
    • 8.8.3. UAE
      • 8.8.3.1. Key Country Dynamics
      • 8.8.3.2. Competitive Scenario
      • 8.8.3.3. Regulatory Framework
      • 8.8.3.4. UAE Market Estimates and Forecasts, 2018 - 2030
    • 8.8.4. Kuwait
      • 8.8.4.1. Key Country Dynamics
      • 8.8.4.2. Competitive Scenario
      • 8.8.4.3. Regulatory Framework
      • 8.8.4.4. Kuwait Market Estimates and Forecasts, 2018 - 2030

Chapter 9. Competitive Landscape

  • 9.1. Market Participant Categorization
    • 9.1.1. Innovators
    • 9.1.2. Market Leaders
    • 9.1.3. Emerging Players
    • 9.1.4. Company Market Share Analysis, 2022
  • 9.2. Company Profiles
    • 9.2.1. Charles River Laboratories International, Inc
      • 9.2.1.1. Company Overview
      • 9.2.1.2. Financial Performance
      • 9.2.1.3. Service Benchmarking
      • 9.2.1.4. Strategic Initiatives
    • 9.2.2. Laboratory Corporation of America Holdings
      • 9.2.2.1. Company Overview
      • 9.2.2.2. Financial Performance
      • 9.2.2.3. Service Benchmarking
      • 9.2.2.4. Strategic Initiatives
    • 9.2.3. IQVIA
      • 9.2.3.1. Company Overview
      • 9.2.3.2. Financial Performance
      • 9.2.3.3. Service Benchmarking
      • 9.2.3.4. Strategic Initiatives
    • 9.2.4. ICON Plc
      • 9.2.4.1. Company Overview
      • 9.2.4.2. Financial Performance
      • 9.2.4.3. Service Benchmarking
      • 9.2.4.4. Strategic Initiatives
    • 9.2.5. Vial
      • 9.2.5.1. Company Overview
      • 9.2.5.2. Financial Performance
      • 9.2.5.3. Service Benchmarking
      • 9.2.5.4. Strategic Initiatives
    • 9.2.6. Medpace
      • 9.2.6.1. Company Overview
      • 9.2.6.2. Financial Performance
      • 9.2.6.3. Service Benchmarking
      • 9.2.6.4. Strategic Initiatives
    • 9.2.7. ProTrials Research, Inc.
      • 9.2.7.1. Company Overview
      • 9.2.7.2. Financial Performance
      • 9.2.7.3. Service Benchmarking
      • 9.2.7.4. Strategic Initiatives
    • 9.2.8. Syneos Health
      • 9.2.8.1. Company Overview
      • 9.2.8.2. Financial Performance
      • 9.2.8.3. Service Benchmarking
      • 9.2.8.4. Strategic Initiatives
    • 9.2.9. Worldwide Clinical Trials, Inc
      • 9.2.9.1. Company Overview
      • 9.2.9.2. Financial Performance
      • 9.2.9.3. Service Benchmarking
      • 9.2.9.4. Strategic Initiatives
    • 9.2.10. ProRelix Services LLP.
      • 9.2.10.1. Company Overview
      • 9.2.10.2. Financial Performance
      • 9.2.10.3. Service Benchmarking
      • 9.2.10.4. Strategic Initiatives

List of Tables

  • Table 1 List of secondary sources
  • Table 2 List of Abbreviations
  • Table 3 North America Ophthalmic Clinical Trials market, by region, 2018 - 2030 (USD Million)
  • Table 4 North America Ophthalmic Clinical Trials market, by Product, 2018 - 2030 (USD Million)
  • Table 5 North America Ophthalmic Clinical Trials market, by Indication, 2018 - 2030 (USD Million)
  • Table 6 North America Ophthalmic Clinical Trials market, by Phase, 2018 - 2030 (USD Million)
  • Table 7 North America Ophthalmic Clinical Trials market, by Sponsor Type, 2018 - 2030 (USD Million)
  • Table 8 U.S. Ophthalmic Clinical Trials market, by Product, 2018 - 2030 (USD Million)
  • Table 9 U.S. Ophthalmic Clinical Trials market, by Indication, 2018 - 2030 (USD Million)
  • Table 10 U.S. Ophthalmic Clinical Trials market, by Phase, 2018 - 2030 (USD Million)
  • Table 11 U.S. Ophthalmic Clinical Trials market, by Sponsor Type, 2018 - 2030 (USD Million)
  • Table 12 Canada Ophthalmic Clinical Trials market, by Product, 2018 - 2030 (USD Million)
  • Table 13 Canada Ophthalmic Clinical Trials market, by Indication, 2018 - 2030 (USD Million)
  • Table 14 Canada Ophthalmic Clinical Trials market, by Phase, 2018 - 2030 (USD Million)
  • Table 15 Canada Ophthalmic Clinical Trials market, by Sponsor Type, 2018 - 2030 (USD Million)
  • Table 16 Europe Ophthalmic Clinical Trials market, by region, 2018 - 2030 (USD Million)
  • Table 17 Europe Ophthalmic Clinical Trials market, by Product, 2018 - 2030 (USD Million)
  • Table 18 Europe Ophthalmic Clinical Trials market, by Indication, 2018 - 2030 (USD Million)
  • Table 19 Europe Ophthalmic Clinical Trials market, by Phase, 2018 - 2030 (USD Million)
  • Table 20 Europe Ophthalmic Clinical Trials market, by Sponsor Type, 2018 - 2030 (USD Million)
  • Table 21 UK Ophthalmic Clinical Trials market, by Product, 2018 - 2030 (USD Million)
  • Table 22 UK Ophthalmic Clinical Trials market, by Indication, 2018 - 2030 (USD Million)
  • Table 23 UK Ophthalmic Clinical Trials market, by Phase, 2018 - 2030 (USD Million)
  • Table 24 UK Ophthalmic Clinical Trials market, by Sponsor Type, 2018 - 2030 (USD Million)
  • Table 25 Germany Ophthalmic Clinical Trials market, by Product, 2018 - 2030 (USD Million)
  • Table 26 Germany Ophthalmic Clinical Trials market, by Indication, 2018 - 2030 (USD Million)
  • Table 27 Germany Ophthalmic Clinical Trials market, by Phase, 2018 - 2030 (USD Million)
  • Table 28 Germany Ophthalmic Clinical Trials market, by Sponsor Type, 2018 - 2030 (USD Million)
  • Table 29 France Ophthalmic Clinical Trials market, by Product, 2018 - 2030 (USD Million)
  • Table 30 France Ophthalmic Clinical Trials market, by Indication, 2018 - 2030 (USD Million)
  • Table 31 France Ophthalmic Clinical Trials market, by Phase, 2018 - 2030 (USD Million)
  • Table 32 France Ophthalmic Clinical Trials market, by Sponsor Type, 2018 - 2030 (USD Million)
  • Table 33 Italy Ophthalmic Clinical Trials market, by Product, 2018 - 2030 (USD Million)
  • Table 34 Italy Ophthalmic Clinical Trials market, by Indication, 2018 - 2030 (USD Million)
  • Table 35 Italy Ophthalmic Clinical Trials market, by Phase, 2018 - 2030 (USD Million)
  • Table 36 Italy Ophthalmic Clinical Trials market, by Sponsor Type, 2018 - 2030 (USD Million)
  • Table 37 Spain Ophthalmic Clinical Trials market, by Dosage Form type, 2018 - 2030 (USD Million)
  • Table 38 Spain Ophthalmic Clinical Trials market, by Indication, 2018 - 2030 (USD Million)
  • Table 39 Spain Ophthalmic Clinical Trials market, by Phase, 2018 - 2030 (USD Million)
  • Table 40 Spain Ophthalmic Clinical Trials market, by Sponsor Type, 2018 - 2030 (USD Million)
  • Table 41 Denmark Ophthalmic Clinical Trials market, by Product, 2018 - 2030 (USD Million)
  • Table 42 Denmark Ophthalmic Clinical Trials market, by Indication, 2018 - 2030 (USD Million)
  • Table 43 Denmark Ophthalmic Clinical Trials market, by Phase, 2018 - 2030 (USD Million)
  • Table 44 Denmark Ophthalmic Clinical Trials market, by Sponsor Type, 2018 - 2030 (USD Million)
  • Table 45 Sweden Ophthalmic Clinical Trials market, by Product, 2018 - 2030 (USD Million)
  • Table 46 Sweden Ophthalmic Clinical Trials market, by Indication, 2018 - 2030 (USD Million)
  • Table 47 Sweden Ophthalmic Clinical Trials market, by Phase, 2018 - 2030 (USD Million)
  • Table 48 Sweden Ophthalmic Clinical Trials market, by Sponsor Type, 2018 - 2030 (USD Million)
  • Table 49 Norway Ophthalmic Clinical Trials market, by Product, 2018 - 2030 (USD Million)
  • Table 50 Norway Ophthalmic Clinical Trials market, by Indication, 2018 - 2030 (USD Million)
  • Table 51 Norway Ophthalmic Clinical Trials market, by Sponsor Type, 2018 - 2030 (USD Million)
  • Table 52 Norway Ophthalmic Clinical Trials market, by Phase, 2018 - 2030 (USD Million)
  • Table 53 Asia Pacific Ophthalmic Clinical Trials market, by region, 2018 - 2030 (USD Million)
  • Table 54 Asia Pacific Ophthalmic Clinical Trials market, by Product, 2018 - 2030 (USD Million)
  • Table 55 Asia Pacific Ophthalmic Clinical Trials market, by Indication, 2018 - 2030 (USD Million)
  • Table 56 Asia Pacific Ophthalmic Clinical Trials market, by Phase, 2018 - 2030 (USD Million)
  • Table 57 Asia Pacific Ophthalmic Clinical Trials market, by Sponsor Type, 2018 - 2030 (USD Million)
  • Table 58 China Ophthalmic Clinical Trials market, by Product, 2018 - 2030 (USD Million)
  • Table 59 China Ophthalmic Clinical Trials market, by Indication, 2018 - 2030 (USD Million)
  • Table 60 China Ophthalmic Clinical Trials market, by Phase, 2018 - 2030 (USD Million)
  • Table 61 China Ophthalmic Clinical Trials market, by Sponsor Type, 2018 - 2030 (USD Million)
  • Table 62 Japan Ophthalmic Clinical Trials market, by Product, 2018 - 2030 (USD Million)
  • Table 63 Japan Ophthalmic Clinical Trials market, by Indication, 2018 - 2030 (USD Million)
  • Table 64 Japan Ophthalmic Clinical Trials market, by Phase, 2018 - 2030 (USD Million)
  • Table 65 Japan Ophthalmic Clinical Trials market, by Sponsor Type, 2018 - 2030 (USD Million)
  • Table 66 India Ophthalmic Clinical Trials market, by Product, 2018 - 2030 (USD Million)
  • Table 67 India Ophthalmic Clinical Trials market, by Indication, 2018 - 2030 (USD Million)
  • Table 68 India Ophthalmic Clinical Trials market, by Phase, 2018 - 2030 (USD Million)
  • Table 69 India Ophthalmic Clinical Trials market, by Sponsor Type, 2018 - 2030 (USD Million)
  • Table 70 Australia Ophthalmic Clinical Trials market, by Product, 2018 - 2030 (USD Million)
  • Table 71 Australia Ophthalmic Clinical Trials market, by Indication, 2018 - 2030 (USD Million)
  • Table 72 Australia Ophthalmic Clinical Trials market, by Phase, 2018 - 2030 (USD Million)
  • Table 73 Australia Ophthalmic Clinical Trials market, by Sponsor Type, 2018 - 2030 (USD Million)
  • Table 74 South Korea Ophthalmic Clinical Trials market, by Product, 2018 - 2030 (USD Million)
  • Table 75 South Korea Ophthalmic Clinical Trials market, by Indication, 2018 - 2030 (USD Million)
  • Table 76 South Korea Ophthalmic Clinical Trials market, by Phase, 2018 - 2030 (USD Million)
  • Table 77 South Korea Ophthalmic Clinical Trials market, by Sponsor Type, 2018 - 2030 (USD Million)
  • Table 78 Thailand Ophthalmic Clinical Trials market, by Product, 2018 - 2030 (USD Million)
  • Table 79 Thailand Ophthalmic Clinical Trials market, by Phase, 2018 - 2030 (USD Million)
  • Table 80 Thailand Ophthalmic Clinical Trials market, by Indication, 2018 - 2030 (USD Million)
  • Table 81 Thailand Ophthalmic Clinical Trials market, by Sponsor Type, 2018 - 2030 (USD Million)
  • Table 82 Latin America Ophthalmic Clinical Trials market, by region, 2018 - 2030 (USD Million)
  • Table 83 Latin America Ophthalmic Clinical Trials market, by Product, 2018 - 2030 (USD Million)
  • Table 84 Latin America Ophthalmic Clinical Trials market, by Indication, 2018 - 2030 (USD Million)
  • Table 85 Latin America Ophthalmic Clinical Trials market, by Phase, 2018 - 2030 (USD Million)
  • Table 86 Latin America Ophthalmic Clinical Trials market, by Sponsor Type, 2018 - 2030 (USD Million)
  • Table 87 Brazil Ophthalmic Clinical Trials market, by Product, 2018 - 2030 (USD Million)
  • Table 88 Brazil Ophthalmic Clinical Trials market, by Indication, 2018 - 2030 (USD Million)
  • Table 89 Brazil Ophthalmic Clinical Trials market, by Phase, 2018 - 2030 (USD Million)
  • Table 90 Brazil Ophthalmic Clinical Trials market, by Sponsor Type, 2018 - 2030 (USD Million)
  • Table 91 Mexico Ophthalmic Clinical Trials market, by Product, 2018 - 2030 (USD Million)
  • Table 92 Mexico Ophthalmic Clinical Trials market, by Indication, 2018 - 2030 (USD Million)
  • Table 93 Mexico Ophthalmic Clinical Trials market, by Phase, 2018 - 2030 (USD Million)
  • Table 94 Mexico Ophthalmic Clinical Trials market, by Sponsor Type, 2018 - 2030 (USD Million)
  • Table 95 Argentina Ophthalmic Clinical Trials market, by Product, 2018 - 2030 (USD Million)
  • Table 96 Argentina Ophthalmic Clinical Trials market, by Indication, 2018 - 2030 (USD Million)
  • Table 97 Argentina Ophthalmic Clinical Trials market, by Phase, 2018 - 2030 (USD Million)
  • Table 98 Argentina Ophthalmic Clinical Trials market, by Sponsor Type, 2018 - 2030 (USD Million)
  • Table 99 Middle East and Africa Ophthalmic Clinical Trials market, by region, 2018 - 2030 (USD Million)
  • Table 100 Middle East and Africa Ophthalmic Clinical Trials market, by Product, 2018 - 2030 (USD Million)
  • Table 101 Middle East and Africa Ophthalmic Clinical Trials market, by Indication, 2018 - 2030 (USD Million)
  • Table 102 Middle East and Africa Ophthalmic Clinical Trials market, by Phase, 2018 - 2030 (USD Million)
  • Table 103 Middle East and Africa Ophthalmic Clinical Trials market, by Sponsor Type, 2018 - 2030 (USD Million)
  • Table 104 South Africa Ophthalmic Clinical Trials market, by Product, 2018 - 2030 (USD Million)
  • Table 105 South Africa Ophthalmic Clinical Trials market, by Indication, 2018 - 2030 (USD Million)
  • Table 106 South Africa Ophthalmic Clinical Trials market, by Phase, 2018 - 2030 (USD Million)
  • Table 107 South Africa Ophthalmic Clinical Trials market, by Sponsor Type, 2018 - 2030 (USD Million)
  • Table 108 Saudi Arabia Ophthalmic Clinical Trials market, by Product, 2018 - 2030 (USD Million)
  • Table 109 Saudi Arabia Ophthalmic Clinical Trials market, by Indication, 2018 - 2030 (USD Million)
  • Table 110 Saudi Arabia Ophthalmic Clinical Trials market, by Phase, 2018 - 2030 (USD Million)
  • Table 111 South Arabia Ophthalmic Clinical Trials market, by Sponsor Type, 2018 - 2030 (USD Million)
  • Table 112 UAE Ophthalmic Clinical Trials market, by Product, 2018 - 2030 (USD Million)
  • Table 113 UAE Ophthalmic Clinical Trials market, by Indication, 2018 - 2030 (USD Million)
  • Table 114 UAE Ophthalmic Clinical Trials market, by Phase, 2018 - 2030 (USD Million)
  • Table 115 UAE Ophthalmic Clinical Trials market, by Sponsor Type, 2018 - 2030 (USD Million)
  • Table 116 Kuwait Ophthalmic Clinical Trials market, by Product, 2018 - 2030 (USD Million)
  • Table 117 Kuwait Ophthalmic Clinical Trials market, by Indication, 2018 - 2030 (USD Million)
  • Table 118 Kuwait Ophthalmic Clinical Trials market, by Phase, 2018 - 2030 (USD Million)
  • Table 119 Kuwait Ophthalmic Clinical Trials market, by Sponsor Type, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Information procurement
  • Fig. 3 Market research approaches
  • Fig. 4 QFD modelling for market share assessment
  • Fig. 5 Market formulation & validation
  • Fig. 6 Commodity flow analysis
  • Fig. 7 Primary research pattern
  • Fig. 8 Primary interviews in North America
  • Fig. 9 Primary interviews in Europe
  • Fig. 10 Primary interviews in Asia Pacific
  • Fig. 11 Primary interviews in Latin America
  • Fig. 12 Primary interviews in MEA
  • Fig. 13 Market Snapshot
  • Fig. 14 Segment Snapshot
  • Fig. 15 Segment Snapshot
  • Fig. 16 Competitive Landscape Snapshot
  • Fig. 17 Ophthalmic Clinical Trials market segmentation
  • Fig. 18 Parent market outlook (2022)
  • Fig. 19 Related/ancillary market outlook (2022)
  • Fig. 20 Market driver relevance analysis (Current & future impact)
  • Fig. 21 Current shared services and outsourcing usage levels
  • Fig. 22 Market restraint relevance analysis (Current & future impact)
  • Fig. 23 Porter's five forces analysis
  • Fig. 24 SWOT analysis, by a factor (political & legal, economic and technological)
  • Fig. 25 Ophthalmic Clinical Trials Market Product outlook: Segment dashboard
  • Fig. 26 Ophthalmic Clinical Trials : Product movement analysis
  • Fig. 27 Devices market, 2018 - 2030 (USD Million)
  • Fig. 28 Drugs market, 2018 - 2030 (USD Million)
  • Fig. 29 Ophthalmic Clinical Trials Market Indication outlook: Segment dashboard
  • Fig. 30 Ophthalmic Clinical Trials : Indication movement analysis
  • Fig. 31 Macular Degeneration market, 2018 - 2030 (USD Million)
  • Fig. 32 Glaucoma market, 2018 - 2030 (USD Million)
  • Fig. 33 Dry eye diseases market, 2018 - 2030 (USD Million)
  • Fig. 34 Retinopathy market, 2018 - 2030 (USD Million)
  • Fig. 35 Uveitis market, 2018 - 2030 (USD Million)
  • Fig. 36 Macular Edema market, 2018 - 2030 (USD Million)
  • Fig. 37 Blepharitis market, 2018 - 2030 (USD Million)
  • Fig. 38 Cataract market, 2018 - 2030 (USD Million)
  • Fig. 39 Optic neuropathy market, 2018 - 2030 (USD Million)
  • Fig. 40 Others market, 2018 - 2030 (USD Million)
  • Fig. 41 Ophthalmic Clinical Trials market Phase outlook: Segment dashboard
  • Fig. 42 Ophthalmic Clinical Trials market: Phase movement analysis
  • Fig. 43 Discovery phase market, 2018 - 2030 (USD Million)
  • Fig. 44 Preclinical phase market, 2018 - 2030 (USD Million)
  • Fig. 45 Clinical phase market, 2018 - 2030 (USD Million)
  • Fig. 46 Ophthalmic Clinical Trials market Sponsor type outlook: Segment dashboard
  • Fig. 47 Ophthalmic Clinical Trials market: Sponsor type movement analysis
  • Fig. 48 Pharmaceutical/ Biopharmaceutical Companies market, 2018 - 2030 (USD Million)
  • Fig. 49 Medical device companies market, 2018 - 2030 (USD Million)
  • Fig. 50 Others market, 2018 - 2030 (USD Million)
  • Fig. 51 Regional marketplace: Segment dashboard
  • Fig. 52 Regional outlook, 2022 & 2030
  • Fig. 53 North America market, 2018 - 2030 (USD Million)
  • Fig. 54 U.S. market, 2018 - 2030 (USD Million)
  • Fig. 55 Canada market, 2018 - 2030 (USD Million)
  • Fig. 56 Europe market, 2018 - 2030 (USD Million)
  • Fig. 57 Germany market, 2018 - 2030 (USD Million)
  • Fig. 58 UK market, 2018 - 2030 (USD Million)
  • Fig. 59 France market, 2018 - 2030 (USD Million)
  • Fig. 60 Italy market, 2018 - 2030 (USD Million)
  • Fig. 61 Spain market, 2018 - 2030 (USD Million)
  • Fig. 62 Denmark market, 2018 - 2030(USD Million)
  • Fig. 63 Sweden market, 2018 - 2030 (USD Million)
  • Fig. 64 Norway market, 2018 - 2030 (USD Million)
  • Fig. 65 Asia Pacific market, 2018 - 2030 (USD Million)
  • Fig. 66 China market, 2018 - 2030 (USD Million)
  • Fig. 67 Japan market, 2018 - 2030 (USD Million)
  • Fig. 68 India market, 2018 - 2030 (USD Million)
  • Fig. 69 Australia market, 2018 - 2030 (USD Million)
  • Fig. 70 South Korea market, 2018 - 2030 (USD Million)
  • Fig. 71 Thailand Markey, 2018 - 2030 (USD Million)
  • Fig. 71 Latin America market, 2018 - 2030 (USD Million)
  • Fig. 72 Brazil market, 2018 - 2030 (USD Million)
  • Fig. 73 Mexico market, 2018 - 2030 (USD Million)
  • Fig. 74 Argentina market, 2018 - 2030 (USD Million)
  • Fig. 75 Middle East & Africa market, 2018 - 2030 (USD Million)
  • Fig. 76 South Africa market, 2018 - 2030 (USD Million)
  • Fig. 77 Saudi Arabia market, 2018 - 2030 (USD Million)
  • Fig. 78 UAE market, 2018 - 2030 (USD Million)
  • Fig. 79 Kuwait market, 2018 - 2030 (USD Million)